Related Experiment Video
Updated: Oct 10, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A
V R Babaev1, L A Gleaves, K J Carter
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA.
Abstract:
The absence of the scavenger receptor A (SR-A)-I/II has produced variable effects on atherosclerosis in different murine models. Therefore, we examined whether SR-AI/II deficiency affected atherogenesis in C57BL/6 mice, an inbred strain known to be susceptible to diet-induced atherosclerotic lesion formation, and whether the deletion of macrophage SR-AI/II expression would modulate lesion growth in C57BL/6 mice and LDL receptor (LDLR)(-/-) mice. SR-AI/II-deficient (SR-AI/II(-/-)) female and male mice on the C57BL/6 background were challenged with a butterfat diet for 30 weeks. No differences were detected in plasma lipids between SR-AI/II(-/-) and SR-AI/II(+/+) mice, whereas both female and male SR-AI/II(-/-) mice had a tremendous reduction (81% to 86%) in lesion area of the proximal aorta compared with SR-AI/II(+/+) mice. Next, to analyze the effect of macrophage-specific SR-AI/II deficiency in atherogenesis, female C57BL/6 mice were lethally irradiated, transplanted with SR-AI/II(-/-) or SR-AI/II(+/+) fetal liver cells, and challenged with the butterfat diet for 16 weeks. In a separate experiment, male LDLR(-/-) mice were reconstituted with SR-AI/II(-/-) or SR-AI/II(+/+) fetal liver cells and challenged with a Western diet for 10 weeks. No significant differences in plasma lipids and lipoprotein profiles were noted between the control and experimental groups in either experiment. SR-AI/II(-/-)-->C57BL/6 mice, however, had a 60% reduction in lesion area of the proximal aorta compared with SR-AI/II(+/+)-->C57BL/6 mice. A similar level of reduction (60%) in lesion area was noted in the proximal aorta and the entire aorta en face of SR-AI/II(-/-)-->LDLR(-/-) mice compared with SR-AI/II(+/+)-->LDLR(-/-) mice. These results demonstrate in vivo that SR-AI/II expression has no impact on plasma lipid levels and that macrophage SR-AI/II contributes significantly to atherosclerotic lesion formation.
Insights
Mice lacking scavenger receptor A (SR-A)-I/II showed significantly reduced atherosclerosis. Macrophage SR-A-I/II expression critically drives atherosclerotic lesion development, independent of plasma lipid levels.
Area of Science:
- Immunology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Scavenger receptor A (SR-A)-I/II absence yields variable atherosclerosis outcomes in murine models.
- C57BL/6 mice are susceptible to diet-induced atherosclerosis.
- LDL receptor (LDLR)(-/-) mice are commonly used models for atherosclerosis research.
Purpose of the Study:
- To investigate the impact of SR-AI/II deficiency on diet-induced atherogenesis in C57BL/6 mice.
- To determine if macrophage-specific SR-AI/II expression influences lesion development in C57BL/6 and LDLR(-/-) mice.
Main Methods:
- SR-AI/II-deficient (SR-AI/II(-/-)) and wild-type (SR-AI/II(+/+)) mice on C57BL/6 background were fed a butterfat diet.
- Bone marrow transplantation models using SR-AI/II(-/-) or SR-AI/II(+/+) fetal liver cells into C57BL/6 and LDLR(-/-) recipients were established.
- Plasma lipids, lipoprotein profiles, and atherosclerotic lesion areas were analyzed.
Main Results:
- SR-AI/II(-/-) mice exhibited 81-86% reduction in aortic lesion area compared to SR-AI/II(+/+) mice, with no plasma lipid differences.
- Mice reconstituted with SR-AI/II(-/-) fetal liver cells showed a 60% reduction in aortic lesion area compared to controls in both C57BL/6 and LDLR(-/-) models.
- No significant differences in plasma lipids or lipoproteins were observed between experimental and control groups.
Conclusions:
- Macrophage SR-AI/II expression is a significant contributor to atherosclerotic lesion formation.
- SR-AI/II deficiency does not affect plasma lipid levels.
- Targeting macrophage SR-AI/II may represent a therapeutic strategy for atherosclerosis.
